Moderna letos vzrostla o 109 % a Jim Cramer ji označil za „konečně znovu investovatelnou“. Firma zároveň potvrdila cíl až 10% růstu tržeb a snížila upravené hotovostní náklady o 26 %.
Moderna (MRNA 3.77%) soared onto the scene in early pandemic days with its messenger RNA technology and delivered a coronavirus vaccine in a matter of months. As the vaccine brought in blockbuster revenue, Moderna's stock price roared higher. In fact, from the start of 2020 through early August 2021, it climbed more than 2,000%.
In recent years, as demand for the coronavirus vaccine declined, the biotech company also saw its profits shrink and even turn into losses. And though the pipeline remained robust, investors had difficulty seeing Moderna as more than a coronavirus vaccine player. All of this led to declines in the stock price, with it sliding more than 80% from its peak.
But Moderna has made significant progress advancing pipeline programs and cost-cutting efforts, and this year, investors have been sitting up and taking notice. The stock has skyrocketed, climbing 109%. Jim Cramer of CNBC's Mad Money calls it "finally investable again." Is Moderna a no-brainer buy on its recent pullback? Let's find out.
Image source: Getty Images.
Moderna's disappointments As mentioned, Moderna struggled in recent years as it took time to transition from a coronavirus vaccine company to a player that investors could see as a multi-product company across treatment areas. Moderna faced its share of disappointments along the path, too, with its respiratory syncytial virus (RSV) vaccine delivering sales that fell short of expectations during its first season on the market and its cytomegalovirus (CMV) candidate failing in late-stage trials.
These sorts of setbacks aren't uncommon for biotech and pharma companies, but following the decline in coronavirus vaccine sales, they added to Moderna's difficulties. But the biotech company progressed in its efforts to realign costs with its opportunities and advance promising programs.
In the latest quarterly update, Moderna reiterated its goal of generating as much as 10% revenue growth this year. And in the quarter, the company delivered a 26% reduction in adjusted cash costs.
Moderna currently has three approved products in the U.S. -- two coronavirus vaccines and its RSV vaccine -- and it may be on the way to launching a fourth. Regulators currently are reviewing the company's flu vaccine candidate, mRNA-1010, and a decision is expected on or before Aug. 5. The company also recently won approval in Europe for its combined coronavirus/flu vaccine -- the world's first.
Today's Change
(
-3.77
%) $
-2.33
Current Price
$
59.49
Future growth drivers Moderna's late-stage candidates and commercialized medicine focus areas are infectious disease vaccines, rare diseases, and oncology. And here, late-stage candidates may drive significant growth in the coming years. For example, intismeran autogene, a personalized cancer therapy, is being studied in several phase 3 trials, and the company's propionic acidemia study is fully enrolled, with data expected later this year. This study may support a regulatory submission.
"Moderna's got a plethora of thoughtful, new products and clear roadmap to profitability for the first time in such a long time," said CNBC's Jim Cramer.
Meanwhile, Moderna stock, though it's soared more than 100% this year, has declined 24% from a peak on July 6. Is the stock a no-brainer buy after this pullback? Moderna is a buy, but investors shouldn't rush to get in on the stock immediately. At today's level, it's reasonable to pick up the shares, but I wouldn't expect them to soar overnight to an out-of-reach price.
Your decision may depend on your investing strategy. Cautious investors might wait a bit longer as Moderna's late-stage candidates progress and then consider picking up a few shares. Aggressive investors, however, may aim to start building a position today, on the dip, and potentially add to this position over time.
Even if Moderna's performance in the second half of the year isn't as spectacular as it was in the first half, that's OK -- the company clearly has reached a key transition point on its path to becoming a multi-product player addressing numerous treatment areas. And that makes it a fantastic stock to buy now or in the coming quarters and hold onto for the long term.
Moderna oznámila první podání dávky v americké studii fáze 1 mRNA-4200 u pacientů s pokročilými nebo metastatickými solidními nádory. Studie bude hodnotit bezpečnost a snášenlivost v kombinaci s inhibitorem kontrolních bodů.
CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.
"mRNA-4200 represents our third off-the-shelf cancer antigen therapy candidate and builds on our efforts to explore broad applicability across multiple cancer types," said David Berman, M.D., Ph.D., Chief Development Officer of Moderna. "By encoding multiple shared tumor targets, this investigational therapy reflects our ongoing efforts to expand the potential of cancer immunotherapy beyond single-target approaches as we continue working to transform cancer care for patients."
The first dose was administered by Dr. William McKean, Clinical Investigator at START Mountain Region in Salt Lake City, Utah, part of The START Center for Cancer Research, the world's largest community-based early-phase oncology site network.
"The first patient dosed in a study represents far more than an operational milestone--it marks the beginning of evaluating a new therapeutic approach that has the potential to impact patients with advanced cancer," said Dr. McKean. "We are proud to continue our collaboration with Moderna and to support the clinical development of mRNA-4200 by providing patients with early access to promising investigational treatments while generating the clinical evidence needed to advance cancer research."
The Phase 1 trial (ClinicalTrials.gov identifier: NCT06880549) is an open-label, multicenter, dose-escalation study that will evaluate the safety and tolerability of mRNA-4200 administered with checkpoint inhibitor therapy in adult participants with advanced solid tumors.
mRNA-4200 was developed in collaboration with Immatics under the Database Program. mRNA-4200 incorporates targets identified using Immatics' XPRESIDENT® target discovery and validation platform and its bioinformatics and AI platform XCUBE®.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Moderna Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the ability for mRNA-4200 to help induce and expand T-cell responses against selected tumor targets; and the potential of Moderna's mRNA platform in oncology. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651 [email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834 [email protected]
Moderna čeká na hospodářské výsledky za 2. čtvrtletí 31. července; Jefferies očekává nevýraznou zprávu s tržbami kolem 100 milionů USD a ztrátou 1,99 USD na akcii. Investoři sledují hlavně data fáze III k personalizované vakcíně proti melanomu mRNA-4157.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company’s late-stage pipeline, including anticipated Phase III melanoma data.
Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.
The analysts forecast a loss of $1.99 per share on revenue of about $100 million, compared with consensus expectations for a loss of $1.97 per share.
“COVID sales are mostly weighted to H2 2026,” Jefferies wrote, noting that lower vaccination rates year-over-year are also expected to weigh on near-term revenue.
The firm expects management could reiterate its 2026 revenue outlook for growth of up to 10% year over year, which would imply revenue of more than $2.1 billion.
Jefferies said potential upside to Moderna’s 2026 sales outlook could come from stabilization in US COVID revenue, which declined from approximately $1.2 billion in 2025. The firm expects international partnerships, including those in Canada, Australia and the UK, to contribute to growth and help create a more balanced revenue mix between US and ex-US markets.
Investors are also watching Moderna’s pipeline progress, particularly Phase III data for mRNA-4157, the company’s personalized cancer vaccine candidate being evaluated in combination with Merck & Co.’s Keytruda in melanoma. Jefferies highlighted the upcoming Phase III INTerpath-001 trial data as a major potential catalyst for the stock, with results expected in the second half of 2026.
The analysts pointed to recent five-year Phase IIb data as supportive of the ongoing Phase III study in high-risk adjuvant melanoma, which enrolled 1,089 patients. Jefferies wrote that management appears confident in the timing of the readout based on event accrual and said a statistically significant result could have a meaningful impact on investor sentiment.
Beyond oncology, Moderna has several additional potential catalysts in 2026, including regulatory action for its mFluSiva flu vaccine candidate, which Jefferies expects could receive US approval by August 5 following a positive advisory committee review. However, the analysts expect commercial sales to begin in 2027.
The firm also highlighted potential Phase III updates for Moderna’s norovirus vaccine candidate mRNA-1403 and pivotal data for mRNA-3927, an investigational treatment for propionic acidemia, as additional events to watch later this year.
Jefferies noted that Moderna’s shares have outperformed the broader biotechnology sector year to date, gaining 124% compared with a 30% rise in the XBI biotechnology ETF, with much of the recent momentum tied to expectations around the company’s oncology pipeline and the potential of its mRNA technology platform.
Shares of Moderna traded hands at $67 on Tuesday afternoon.
Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesJuly 9 (Reuters) - Moderna (MRNA.O), opens new tab said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Here are the details:
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The agreement gives the participating countries - Austria, Denmark, Ireland, Luxembourg, Norway and Portugal - access to up to 24 million doses of the vaccine over as many as four years, the company said.
The vaccine, mRESVIA, will be supplied in a ready-to-use, single-dose pre-filled syringe, making administration easier for healthcare professionals, Moderna said.
The company had a similar joint procurement framework agreement with the European Commission for COVID-19 vaccines last year.
mRESVIA is authorized in the European Union to prevent lower respiratory tract disease caused by RSV in adults.
RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults.
Moderna has four approved mRNA vaccines for respiratory infections, including a combined influenza and COVID-19 vaccine authorized in Europe.
Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Moderna letos více než zdvojnásobila cenu akcií, protože trh sází na její pipeline a pokrok u vakcíny proti chřipce. Firma míří k uvedení několika produktů v letech 2027 a 2028, včetně sezónní vakcíny proti chřipce, kombinované vakcíny proti chřipce/COVID-19 a norovirové vakcíny.
Moderna's (MRNA +2.57%) share price has more than doubled this year as the market has grown increasingly optimistic about the company's pipeline and encouraging regulatory progress for its flu vaccine. But after such a sharp rally, it's fair to ask whether there's still an opportunity here to make some money.
What comes next for Moderna? The investment case for Moderna isn't just about COVID-19 vaccines anymore. It's about what comes next.
Today, the company has three commercial products, multiple late-stage vaccine programs, and an expanding pipeline that stretches well beyond infectious diseases. Moderna is developing personalized cancer vaccines in partnership with Merck and pursuing therapies for rare genetic disorders.
Image source: Getty Images.
The company is now preparing for multiple product launches in 2027 and 2028, including seasonal flu, a flu/COVID-19 combination vaccine, and a norovirus vaccine. That's a dramatically different company than the one investors knew during the pandemic, when nearly all of its revenue came from a single COVID-19 vaccine. If even a handful of these late-stage programs reach the market, Moderna could become a much more diversified biotechnology company with multiple sources of recurring revenue. And the financial picture is improving, too.
Possible breakeven by 2028 During the first quarter of 2026, Moderna generated $389 million in revenue, up from $108 million a year earlier. Although the company still posted a net loss, it finished the quarter with approximately $7.5 billion in cash and investments, providing it with ample resources to continue funding its research pipeline. Management also continues targeting up to 10% revenue growth in 2026 while working toward cash breakeven by 2028.
The biggest near-term catalyst may be the company's flu vaccine. An FDA advisory committee recently voted 9-0 to recommend approval for Moderna's seasonal influenza vaccine for adults 50 and older. While the FDA isn't required to follow the panel's recommendation, it often does, with a final decision expected in early August. Of course, that doesn't mean the stock is without risk.
Today's Change
(
2.57
%) $
2.05
Current Price
$
81.81
High expectations for Moderna Much of Moderna's recent rally reflects higher expectations, and several important clinical readouts (including late-stage melanoma data) are still ahead. Any disappointing results could quickly change investor sentiment. But it's still hard to justify passing on the stock, even after its latest run.
You see, Moderna is no longer just a play on COVID-19. It's actually becoming a highly successful, diversified biotechnology company with multiple opportunities to create value over the next several years. After such a strong run, don't expect the shares to move in a straight line. But if you're thinking long-term, Moderna still offers considerable upside.
Moderna na Science Day představila plán rozšířit platformu mRNA mimo vakcíny do onkologie, autoimunitních nemocí a buněčné terapie. Akcie za týden vzrostly o 33,5 %.
Key Takeaways Moderna outlined a strategy to expand its mRNA platform beyond vaccines into multiple therapies.Shares of the company rallied as Science Day spotlighted oncology, autoimmune and cell therapy programs.MRNA expects early-stage programs, including in vivo CAR-T and CAR-M therapies, to enter the clinic by 2027. Shares of Moderna (MRNA - Free Report) have surged 33.5% over the past week, adding nearly $8 billion to the company's market value.
The rally was sparked by Moderna's Science Day, where management outlined its vision to evolve beyond vaccines into a diversified biotechnology company. The event showcased how the company plans to leverage its messenger RNA (mRNA) platform across multiple therapeutic areas, including oncology, autoimmune diseases and cell therapy, while unveiling a new research and early development framework to accelerate pipeline innovation.
Moderna Leverages Its mRNA Platform Beyond VaccinesAs part of its long-term strategy, the company has grouped its business into three development horizons. Moderna emphasized that its commercial products, late-stage pipeline assets — including respiratory vaccine programs and its Merck (MRK - Free Report) -partnered personalized cancer therapy — as well as investigational rare disease therapies, represent Horizon 1, the foundation of its current business.
Beyond these established programs, Moderna introduced Horizon 2 and Horizon 3, underscoring its ambition to expand the application of its mRNA platform well beyond vaccines. Horizon 2 comprises emerging therapeutic modalities already in clinical development, including cancer antigen therapies, T-cell engagers, cell therapy enhancers and an investigational therapy for multiple sclerosis.
Horizon 3 comprises earlier-stage research programs that have not yet entered the clinic but are expected to advance into first-in-human studies before the end of 2027. These include in vivo CAR-T and CAR-M cell therapies, which could become the company's next-generation growth platforms.
Moderna is not alone in broadening the application of mRNA technology. The company’s rival BioNTech (BNTX - Free Report) is also leveraging its mRNA platform beyond vaccines and building an extensive pipeline across oncology and other disease areas to diversify its long-term growth prospects.
Why Investors Are Paying Attention to MRNA StockInvestors appear to have welcomed Moderna's efforts to expand the use of its mRNA platform beyond vaccines. Among the highlights was mRNA-6007, the company's first investigational in vivo CAR-T candidate for autoimmune diseases such as systemic lupus erythematosus (SLE), representing Moderna's entry into cell therapies. The program is part of the company's Horizon 3 pipeline, which management expects to advance into clinical studies by the end of 2027.
More broadly, the event underscored Moderna's strategy to use its mRNA platform to develop multiple classes of medicines spanning oncology, rare diseases, autoimmune disorders and cell therapies. By broadening the application of its mRNA platform across diverse therapeutic areas, the company aims to diversify future revenue streams beyond respiratory vaccines. The strategy appears to have resonated with investors, helping lift the stock to a 52-week high of $81.40.
MRNA’s Price Performance, Valuation & EstimatesShares of Moderna have skyrocketed more than 170% year today, significantly outperforming the industry’s 5.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, the company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 13.16 times forward 12-month sales, higher than the industry average of 1.91 times.
Image Source: Zacks Investment Research
Estimates for Moderna’s 2026 and 2027 bottom line have declined over the past 60 days.
Image Source: Zacks Investment Research
Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Akcie společnosti Moderna vyskočily o 9,2 % po pozitivních datech o chřipkové vakcíně a nových informacích o pipeline. Poradní panel FDA jednomyslně podpořil vakcínu mRNA-1010/mFLUSIVA pro dospělé od 50 do 64 let a pro osoby ve věku 65 let a starší.
Moderna Inc. MRNA shares rose 9.2% on Thursday, making the biotechnology company one of the top performers in the S&P 500.
Investors responded positively to new pipeline updates, encouraging influenza vaccine data, and favorable analyst commentary.
The stock extended its recent rally after climbing to a new annual high on Wednesday.
At one point, shares gained nearly 12% as investors welcomed the company's latest Science Day presentation and progress across its mRNA development programs.
Investor sentiment also received a boost after an FDA advisory panel unanimously supported Moderna's mRNA-1010/mFLUSIVA influenza vaccine for adults aged 50 to 64 and those 65 and older.
The recommendation comes ahead of a Prescription Drug User Fee Act (PDUFA) decision expected on Aug. 5, 2026, as well as planned global regulatory filings.
During its recent Science Day presentation, Moderna outlined plans to expand its mRNA platform beyond infectious disease vaccines into oncology, autoimmune diseases and other therapeutic areas.
The company showcased programs targeting multiple myeloma, ovarian cancer and in vivo CAR-T therapies, while emphasizing increased use of artificial intelligence, machine learning, automation and robotics to accelerate research and development.
Plans to begin the in vivo CAR-T program mRNA-6007 in 2027 also contributed to investor optimism.
Chief Executive Officer Stéphane Bancel said the company's strategy extends across multiple areas of development.
Working across three strategic horizons, we are applying our mRNA platform expertise to validate, scale and expand our modalities, with new modalities in the clinic, including T-cell engagers, and new modalities soon to be in the clinic, like in vivo CAR-T. At the same time, we are driving innovation by using data, AI and machine learning, and robotics to accelerate discovery and continuously improve how we execute for near-term growth while fuelling the next generation of mRNA medicines for patients around the world.
Analysts remained constructive on Moderna's long-term prospects despite differing views on the pace of commercialization.
Jefferies maintained a Hold rating and a $45 price target, stating that while eventual approval of the influenza vaccine appears likely, meaningful flu-related revenue is not expected until 2027.
Piper Sandler took a more optimistic stance, raising its price target to $77 from $69 while reiterating an Overweight rating following the recent rally.
The positive analyst commentary added to growing optimism surrounding Moderna's expanding pipeline beyond COVID-19 vaccines.
Financial position remains supported by cash reservesDespite renewed enthusiasm surrounding its research programs, Moderna continues to operate at a loss as it invests heavily in product development.
The company generated approximately $389 million in quarterly revenue and about $1.94 billion in trailing 12-month revenue.
However, it reported a net loss of roughly $1.34 billion in the latest quarter and an EBITDA loss of approximately $1.28 billion. Free cash flow stood at negative $692 million.
Moderna has approximately $5.21 billion in cash and short-term investments, a current ratio of 2.4 and long-term debt of about $1.25 billion, providing financial flexibility as it continues investing in its pipeline.
CNBC's Jim Cramer also expressed optimism about the company's direction.
“For the first time in a long time, the company seems like it has something to get excited about", Cramer said on Wednesday.
He added that Moderna's “plethora of thoughtful, new products” is presenting a clear roadmap to profitability for the first time in a long while.
However, Cramer also urged patience, saying, “I recommend waiting for a pullback before you buy. Take your time. I think Moderna’s got a bright future though, but it’ll take years to get there.”
Moderna po Science Day vzrostla téměř o 20 % díky nové strategii mRNA pro léčbu rakoviny a vzácných nemocí. Růst podle článku podpořil short squeeze, když před akcí byl short interest přes 16,5 % a shortaři potřebovali více než 10 dnů na pokrytí svých pozic.
Shares of Moderna NASDAQ: MRNA are behaving like it's 2020. The stock is up nearly 20% since the company’s Science Day event.
At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It’s a move beyond vaccines, and investors seem to like it.
Get Moderna alerts:
Looks, however, can be deceiving. Prior to the event, MRNA had short interest of over 16.5% which required over 10 days for short sellers to cover their positions.
The result? A classic short squeeze that has sent the stock to nearly double its consensus price target of around $37 as of June 30.
However, the price movement by itself isn’t disqualifying. The expansion of mRNA as a treatment for diseases is where the promise has always been. Therefore, investors are left with a decision ahead of its Q2 2026 earnings report, scheduled for July 30.
Why mRNA Still MattersThe promise of mRNA is that it changes how medicine gets made. Traditional drugs are manufactured in factories and injected into the body. mRNA medicines work differently. They deliver genetic instructions, and the body's own cells produce the protein needed to treat the disease.
That matters for two reasons. The same platform can be reprogrammed for different diseases by changing only the instructions. And that flexibility could make drug development faster and more efficient over time.
COVID-19 vaccines proved the platform works in infectious disease. The question Moderna is now trying to answer is whether the same approach can deliver meaningful results for cancer, autoimmune diseases, and rare diseases.
If the answer is yes, the platform becomes far more valuable than its vaccine franchise alone. That's the long-term story driving the recent move.
3 Horizons, 1 Long RunwayAt Science Day, Moderna organized its business into three "Horizons" that map how the platform scales over time.
Horizon 1 is Moderna’s commercial engine. It includes four approved vaccines (Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX), the investigational intismeran autogene cancer therapy, and a rare disease franchise led by a propionic acidemia treatment. This accounts for the bulk of the company’s current revenue.
Horizon 2 is the next wave. T-cell engagers targeting multiple myeloma and ovarian cancer, cancer antigen therapies for solid tumors and Lynch syndrome, and a multiple sclerosis therapeutic linked to the Epstein-Barr virus. Most are in Phase 1 or Phase 2 trials. The earliest meaningful readout is mRNA-1195 for multiple sclerosis, which is expected in the second half of 2026.
Horizon 3 is the long-term bet. The headline asset is mRNA-6007, an in vivo CAR-T therapy aimed at lupus. Moderna expects this to enter human trials by the end of 2027.
That’s a whole lot of potential. However, none of Horizon 2 or Horizon 3 will generate revenue until after 2028. Phase 1 and Phase 2 readouts are clinical milestones, not commercial ones. The path from trial to approval to launch takes years.
Why Caution Is WarrantedOn June 26, the day after Moderna’s Science Day event, Piper Sandler reiterated its Overweight rating on MRNA and raised its price target to $77 from $69. Even at the former price target, Piper Sandler was already one of the most bullish analysts.
It’s important to note, however, that the new price target doesn’t leave much upside for MRNA after its recent gains. Analysts may be holding off on issuing opinions until the company’s earnings report, especially since there won’t be any revenue or earnings from these new initiatives for several years.
That puts the entire burden on Horizon 1. The four approved vaccines, the intismeran Phase 3 program, and disciplined cash management have to fund the pipeline long enough for the platform story to pay off.
That’s why long-term investors who aren’t in the stock should wait for a better entry point. It’s also a reason for current shareholders to take some risk off the table.
Where the Squeeze Logically Gives BackThe most likely first pullback level is $60. It's a round-number psychological level and represents a healthy give-back of about half the move off the mid-June breakout. Pullbacks of that size are normal after a sharp rally; they are normal profit-taking and leave the bullish structure intact. Anyone trimming into the squeeze would look to add back near this level.
The deeper, higher-conviction support is $55. That was the top of the April-to-June trading range, and the launch point of the Science Day breakout candle. Prior resistance becomes new support, and this is where the squeeze froth fully resets without breaking the thesis.
The line in the sand is $52, where the 50-day SMA sits at $51.83. A close below that level would mean the breakout has failed, and the stock has fallen back into the range it traded in before Science Day. At that point, the platform re-rate needs a fresh catalyst, such as the July 30 earnings report, to reassert itself.
Should You Invest $1,000 in Moderna Right Now?Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Moderna oznámila, že poradní výbor FDA jednomyslně podpořil její mRNA vakcínu proti chřipce mRNA-1010 pro osoby ve věku 50 let a starší. Schválení může přijít už 5. srpna.
After a significant slump following the height of the COVID-19 pandemic, Moderna (MRNA +0.53%) share prices have ripped higher over the past year, surging nearly 150%. Various factors have driven Moderna's rebound, including regulatory progress on one of its most anticipated products.
Yet even as this news, plus additional promising announcements, suggests a further recovery ahead for this pandemic-era favorite, keep in mind how much of this "comeback potential" is already priced into one of the hottest biotech stocks.
Image source: Getty Images.
Why Moderna is surging higher On June 18, Moderna disclosed how a Food and Drug Administration (FDA) advisory committee voted unanimously that the benefits of its mRNA-based flu vaccine, mRNA-1010, outweigh the risks among patients aged 50 or over. The FDA could approve mRNA-1010 as soon as Aug. 5. The candidate is also currently under regulatory review in Australia, Canada, and the European Union.
Today's Change
(
0.53
%) $
0.37
Current Price
$
70.07
Other news has also lifted sentiment. The company's recent investor day also included a surprise announcement that it is gearing up to develop an in vivo CAR-T candidate. Success with this endeavor could help Moderna diversify into respiratory, oncology, and rare-disease treatments.
Tread carefully amid the hype There's substance to the market's bullish shift on Moderna, but things have arguably gotten out of hand. After its hot run, the company now has a market cap of around $26.7 billion. As Moderna is currently unprofitable, this valuation is clearly based upon the future potential of its non-COVID-19 products. However, the estimated total addressable market for flu vaccines is only around $9.5 billion. Moderna will likely need to gain dominant market share for this to translate into sales and earnings that help justify the stock's current valuation.
Even when factoring in future potential with CAR-T and other treatments, many of these early products remain years away from commercialization. In the meantime, as Moderna continues to burn through its cash position to fund its post-COVID-19 comeback, the company could be at increased risk of a dilutive equity offering. Even if you're bullish on Moderna's long-term rebound potential, you may want to wait until some of the latest hype fades before buying.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Moderna. The Motley Fool has a disclosure policy.
Moderna představila plán rozšířit byznys mimo vakcíny a akcie vyskočily téměř o 13 % na 52týdenní maximum. První in vivo CAR-T kandidát mRNA-6007 chce dostat do klinických studií do konce roku 2027.
Key Takeaways Moderna outlined a three-horizon pipeline strategy to diversify beyond vaccines across new therapies.MRNA plans to advance its first in vivo CAR-T candidate into clinical studies by the end of 2027.Moderna highlighted AI integration to speed drug discovery and cited several upcoming clinical catalysts. Shares of Moderna (MRNA - Free Report) rose nearly 13% on Friday after the company unveiled a long-term strategy to transform itself from a vaccine-maker into a diversified biotechnology company.
Moderna Looks Beyond Its Vaccine BusinessAt its Science Day event, Moderna outlined plans to expand beyond its traditional vaccine business by leveraging its messenger RNA (mRNA) platform across multiple therapeutic areas.
To execute this strategy, the company has divided its pipeline into three horizons. Horizon 1 comprises its commercial products and late-stage pipeline assets, including the Merck (MRK - Free Report) -partnered personalized cancer therapy, intismeran autogene, and rare disease therapeutics.
Horizon 2 focuses on emerging clinical programs currently being evaluated in early-stage studies. These include cancer antigen therapies such as mRNA-4359, mRNA-4106 and mRNA-4200, along with T-cell engagers, cell therapy enhancers and an investigational therapy for multiple sclerosis.
In contrast, Horizon 3 or "future modalities," consists of earlier-stage research programs that have yet to enter the clinic. These include in vivo CAR-T and CAR-M cell therapies, which could become the company's next-generation growth platforms. As part of this horizon, Moderna unveiled mRNA-6007, its first in vivo CAR-T therapy, which it plans to develop for systemic lupus erythematosus (SLE) and other B-cell-mediated autoimmune diseases. The company expects to advance the candidate into clinical studies by the end of 2027.
MRNA Stock PerformanceThe broader pipeline strategy highlights Moderna's efforts to leverage its mRNA platform beyond vaccines and build multiple long-term growth franchises across oncology, rare diseases, autoimmune disorders and cell therapies. Investors appear to have welcomed this diversification strategy, helping lift the stock to a 52-week high of $69.29.
Year to date, the stock has skyrocketed 128% compared with the industry’s 5% growth.
Image Source: Zacks Investment Research
Moderna Explores AI to Accelerate Drug DiscoveryBeyond expanding its pipeline, Moderna also highlighted plans to expand its use of artificial intelligence (AI) to accelerate drug discovery and development. The company is integrating AI, machine learning and platform data to improve target identification, optimize molecule design and streamline clinical development.
Management believes these capabilities will help improve R&D productivity and support the development of future mRNA-based medicines across multiple therapeutic areas.
Upcoming Catalysts Drive MRNA StockSeveral near-term catalysts could support Moderna’s long-term growth strategy. These include a potential FDA approval of its seasonal influenza vaccine, which is expected early next month.
Investors will also be watching several important clinical milestones that could serve as catalysts for the stock over the coming quarters. These include phase III data on intismeran in melanoma, a readout from the company's late-stage norovirus vaccine program and data from the registrational study evaluating its propionic acidemia candidate.
MRNA’s Zacks RankModerna currently carries a Zacks Rank #3 (Hold).
Key Picks Among Biotech StocksSome better-ranked stocks from the sector are Immunocore (IMCR - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost nearly 11% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.56 to $4.27. INDV’s shares are up nearly 17% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.
Moderna vzrostla o 14 % na 69,29 USD a výrazně překonala Merck i Pfizer. Růst podporuje optimismus kolem pipeline a dřívější souhlas poradního panelu FDA s vakcínou proti chřipce mFlusiva.
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29.
The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% to $24 and change. On a single-session basis, Moderna stock is clearly leading the vaccine complex.
There’s no fresh same-day headline that cleanly explains the size of the move. Instead, traders appear to be extending momentum from a de-risking event last week, combined with bullish pipeline messaging and a likely short-covering component in a heavily traded name.
FDA Panel De-Risking and Pipeline Optimism Fuel the Run The biggest catalyst in the rear-view mirror was an FDA advisory committee unanimously endorsing Moderna’s flu vaccine, mFlusiva (mRNA-1010), for adults 50 and older. That vote is a key step ahead of the August 5, 2026 PDUFA date, which would mark Moderna’s fifth approved product if cleared.
Moderna also held a Science Day this week highlighting its push beyond vaccines into oncology and autoimmune disease, including T-cell engagers, an in-vivo CAR-T program, and a personalized cancer vaccine, with messaging around a 2028 break-even goal. Jefferies raised its MRNA price target to $53 from $45, while keeping a Hold rating.
The fundamental backdrop has been improving. Moderna’s Q1 2026 revenue came in at $389 million, up 264% year over year and beating consensus by 65%, with the company reaffirming guidance for up to 10% revenue growth in 2026 in its most recent 10-Q filing.
Moderna Leads, but Merck Won the Week Zoom out and the picture gets more nuanced. Over the past month, Moderna stock is up 45%, while Merck stock has added 7% and Pfizer stock has fallen 6%. Year to date, the gap is even wider, with Moderna up 130% against Merck’s 21% gain and Pfizer’s modest 3% decline.
Pfizer remains the laggard. Comirnaty revenue fell 59% to $232 million in Q1 2026, underscoring how reliant the company still is on its non-COVID portfolio. Pfizer’s forward P/E ratio of 8x and 7% dividend yield keep it a value-and-income story rather than a momentum trade.
The Street Is Still Cautious on Moderna For all the enthusiasm, the sell-side has not fully signed off. The MRNA stock consensus analyst target price sits at $43.45, well below today’s quote, with 16 Hold ratings against a smaller cluster of Buys and Sells. Leerink sits near $24 and Morgan Stanley near $33, meaning Moderna stock is running ahead of where most of the Street is positioned.
Moderna’s insiders have been net sellers as well, with 75 recent insider transactions tilting toward selling. That doesn’t invalidate the bull case, but it argues for keeping position sizes modest given MRNA stock’s volatility profile and forward P/E ratio of 23x on still-uncertain forward earnings.
What to Watch Next The next clear data point is the August 5, 2026 FDA decision on mRNA-1010. Investors can also watch upcoming Phase 3 readouts for norovirus, intismeran in melanoma, and propionic acidemia, any of which could shift the medium-term narrative for Moderna.
For today, the answer to the title’s question is clear. On a single-day basis, and across the past month and year to date, Moderna stock is decisively outperforming Merck stock and Pfizer stock. Whether the stock can hold above the $65 level into next week may say more about momentum traders than about the underlying biotech story.
Moderna letos vzrostla o něco více než 100 % a čeká na rozhodnutí FDA o vakcíně proti chřipce mRNA-1010 do 5. srpna. Poradní výbor ji jednomyslně podpořil.
Moderna (MRNA 1.03%) has been on fire this year. As of this writing, the company's shares have slightly more than doubled to date. What's more, the biotech has an important catalyst on the horizon. Let's find out whether there is any upside left for the company.
Image source: Getty Images.
Racing toward an approval Moderna has been working on an influenza vaccine, mRNA-1010. It submitted regulatory applications for this candidate earlier this year. The U.S. Food and Drug Administration (FDA) should approve or reject Moderna's application by Aug. 5. It's an important date for the biotech company, as an approval in this field might allow it to establish itself as a leader in the flu market. True, plenty of flu vaccines exist, but their efficacy is usually not very impressive, typically between 40% to 60% in the U.S. In phase 3 studies, mRNA-1010 performed better than approved vaccines in patients aged 50 and older who tend to be more at risk of severe cases of the disease, hospitalization, and death.
And if there was any doubt about whether mRNA-1010 would get the FDA's green light, recent developments have made that outcome practically certain. Members of an advisory committee convened by the FDA to give their opinion on whether mRNA-1010 should earn approval unanimously voted in favor. The health regulatory agency doesn't always follow the advice of these experts, but it almost always does. It would be surprising if mRNA-1010 doesn't get the nod.
Today's Change
(
-1.03
%) $
-0.62
Current Price
$
59.80
What does this mean for the stock? Moderna's shares soared after the advisory committee's vote of confidence for mRNA-1010. So, it's likely the market has already priced in a positive outcome, and the stock won't move much once mRNA-1010 is approved. However, there are still good reasons to invest in Moderna. The company is once again demonstrating its innovative qualities with mRNA-1010, just as it did with its coronavirus vaccine, which became a leader in that niche. The flu vaccine market isn't that large. According to some estimates, it was worth $8.9 billion last year, although it will continue growing at a good clip for the foreseeable future. Moderna's potential sales in this niche alone do not justify its $24.5 billion market cap, especially given that it generates meager revenue from its currently approved products.
That said, the vaccine maker has a rich pipeline with several products that could become key growth drivers. For instance, Moderna is developing mRNA-4157, an investigational personalized cancer vaccine that has shown highly encouraging clinical trial results and is now undergoing several phase 2 and phase 3 studies. Moderna is also going after difficult targets. The company is developing an HIV vaccine. Moderna's success in the flu vaccine market will help it pursue even more lucrative markets. Over the next five years, the company could have a much broader portfolio of approved products while generating strong revenue and earnings. That's why Moderna's shares are still attractive, even after climbing by about 100% this year.
Moderna uvedla, že její program mRNA-2808 v oblasti mnohočetného myelomu podporuje rychlý postup mRNA-2151 do rané fáze vývoje u ovariálního karcinomu. Zároveň představila in vivo CAR-T mRNA-6007 pro autoimunitní onemocnění.
Provides broad overview of Company's research and early development programs expected to continue to fuel future growth
Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer
Introduces in vivo CAR-T modality with mRNA-6007 moving into early development for autoimmune diseases
CAMBRIDGE, MA / ACCESS Newswire / June 25, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced research and early development updates at its Science Day event.
"As we execute our strategic plan to become a diversified, multi-modality biotechnology company, we are preparing to manage three commercial franchises, Infectious Disease Vaccines, Intismeran, and Rare Disease Therapeutics, while advancing a broad mRNA pipeline and continuing to invest in research and development," said Stéphane Bancel, CEO of Moderna. "Working across three strategic horizons, we are applying our mRNA platform expertise to validate, scale and expand our modalities, with new modalities in the clinic, including T-cell engagers, and new modalities soon to be in the clinic, like in vivo CAR-T. At the same time, we are driving innovation by using data, AI and machine learning, and robotics to accelerate discovery and continuously improve how we execute for near-term growth while fueling the next generation of mRNA medicines for patients around the world. We are fortunate to have the privilege to make medicine at this moment in time."
Moderna is executing a strategy that balances near-term growth with long-term innovation. Building on the momentum of its four approved products -- Spikevax®, mRESVIA®, mNEXSPIKE® and mCOMBRIAX® -- the Company is driving growth through infectious disease launches, geographic expansion, and the advancement of late-stage pipeline opportunities, including its investigational intismeran autogene therapy and propionic acidemia therapeutic.
In parallel, Moderna Research and Early Development, mRED, is focused on emerging and future modalities to advance high-potential programs toward clinical proof-of-concept and first-in-human milestones. Moderna's Scientific Intelligence Engine is harnessing data, AI and machine learning, automation, and robotics to accelerate discovery and continuously improve how the Company operates.
Platform Strategy
Moderna's platform is built on three integrated pillars: mRNA science, delivery science and manufacturing processes. By combining the components of its mRNA platform, the Company creates modalities, or groups of potential mRNA medicines that share similar mRNA technologies, delivery technologies, and manufacturing processes to achieve shared product features.
These modalities turn platform expertise into repeatable development by generating proof-of-concept data from sentinel programs to de-risk modalities and accelerate development plans. Moderna has established and scaled multiple modalities, including infectious disease vaccines, intismeran autogene, and rare disease therapeutics, to validate its platform and considers these its Horizon 1 established modalities. Horizon 1 comprises Moderna's late-stage and approved products, while continuing to enable innovation in these established modalities, and drives an end-to-end path from discovery through commercialization.
Moderna Research and Early Development
Moderna Research and Early Development (mRED) builds Moderna's next growth horizons by advancing differentiated, platform-enabled modalities. Horizon 2 emerging modalities and Horizon 3 future modalities are led by mRED to scale and expand the Company's mRNA platform. Horizon 2 modalities are in the clinic and awaiting human proof-of-concept. The majority are in Phase 1/2 studies in oncology, with a multiple sclerosis therapeutic in Phase 2. Horizon 3 modalities have the potential to advance to first-in-human clinical trials by the end of 2027.
Scientific Intelligence Engine
Data from across Moderna's three Horizons powers an AI-enabled engine for accelerated discovery. This includes data generated by the Company's mRNA platform as well as internal proprietary and publicly available data. The engine feeds a continuous learning loop that helps de-risk program development through mRNA platform innovation.
Early Pipeline Progress
Highlights from Moderna's early-stage pipeline include:
Horizon 2
mRNA-4106 (Cancer antigen therapy): Encodes shared nonmutated cancer testes antigens designed to elicit T-cell immune responses against tumor cells. The Phase 1 study is ongoing with mRNA-4106 as monotherapy in advanced solid tumors.
mRNA-4200 (Cancer antigen therapy): Encodes shared nonmutated tumor associated antigens designed to elicit T-cell immune responses against tumors. The Phase 1 study is planned in combination with pembrolizumab in advanced solid tumors.
mRNA-4194 (Cancer antigen therapy): Encodes frameshift peptides frequently identified in Lynch syndrome, an inherited condition that increases cancer risk. The Phase 1/2 study is planned to start in Lynch syndrome this summer with the goal of preventing progression of pre-malignancies to cancer. mRNA-4194 represents Moderna's first investigational cancer prevention program.
mRNA-4359 (Cancer antigen therapy): Designed to elicit T-cell immune responses against tumor and immunosuppressive cells, the Phase 1/2 study is ongoing with the Phase 2 portion including cohorts in first-line metastatic melanoma and first-line metastatic non-small cell lung cancer (NSCLC).
mRNA-2808 (T-cell engager): Designed to use multiplexed T-cell engagers to improve efficacy and overcome mechanisms of resistance for multiple myeloma, the Phase 1/2 study is ongoing and includes three distinct T-cell engagers against clinically validated targets.
mRNA-2151 (T-cell engager): Designed to improve anti-tumor efficacy in solid tumors, this preclinical multiplexed T-cell engager program is moving toward early development in ovarian cancer. Advancement of mRNA-2151 is supported by an encouraging early clinical signal with mRNA-2808.
mRNA-1195 (Multiple sclerosis therapeutic): Designed to address Epstein-Barr virus (EBV)-associated conditions including multiple sclerosis, the Phase 1 part B data is expected in the second half of 2026. The Phase 2 study in multiple sclerosis is ongoing; with its sentinel cohort fully enrolled, the DSMB has recommended to proceed with dose escalation.
Horizon 3
mRNA-6007 (In vivo CAR-T): Designed to enable deep B-cell depletion for autoimmune conditions using a multiplexed mRNA approach with targeted lipid nanoparticles, the program aims to deliver mRNA into immune cells in vivo, enabling transient CAR expression and potential immune reset. The initial clinical focus is systemic lupus erythematosus (SLE) and other B cell mediated autoimmune diseases.
For more details on the data and programmatic updates shared during Moderna's Science Day investor event today, please visit "Events and Presentations" in the Investors section of the Moderna website.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Spikevax®, mRESVIA®, mNEXSPIKE® and mCOMBRIAX® are registered trademarks of Moderna.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential of Moderna's mRNA platform and promise as a multi-modality biotechnology company; Moderna's potential three commercial franchises; Moderna's ability to use data, AI and machine learning, and robotics to drive innovation; anticipated infectious disease launches and geographic expansion; Moderna's late-stage pipeline opportunities in intismeran and propionic acidemia; the potential of mRNA-4194 to address Lynch syndrome and prevent cancer from occurring; Moderna's T-cell engager modality and the encouraging early clinical signal with mRNA-2808; Moderna's in vivo CAR-T modality and the potential in autoimmune diseases; Moderna's ongoing and planned clinical studies; and anticipated progress and milestones for Moderna's programs, including anticipated timing. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
###
Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651 [email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834 [email protected]
FDA poradní výbor bude hodnotit vakcínu proti chřipce mFlusiva od Moderna, přičemž briefing nenašel žádné zásadní nedostatky. Hlasování se zaměří na poměr rizik a přínosů u dospělých ve věku 50 až 64 let a 65 let a více.
FDA Advisory Committee To Review Moderna Flu Vaccine ApplicationThe company submitted an application in December 2025 for mFlusiva (mRNA-1010), an mRNA-based trivalent influenza vaccine.
The VRBPAC panel’s vote will focus on the risk-benefit profile of mFlusiva for influenza prevention in adults aged 50 to 64 years, and in the 65-year-and-older population.
The briefing document released on Tuesday identified no major deficiencies.
The primary efficacy analysis demonstrated that mRNA-1010 (TIV) met all prespecified sequential success criteria—noninferiority, superiority, and super-superiority—relative to the standard-dose (SD) comparator.
Questions Around Comparator Choice And Clinical DataThe VRBPAC members will consider whether the standard-dose flu vaccine used as the control was the most appropriate comparator. High-dose, recombinant, and adjuvanted flu vaccines are generally preferred for adults 65 and older.
FDA Decision Timeline And Proposed Approval StrategyFollowing a Type A meeting, the FDA assigned a Prescription Drug User Fee Act goal date of August 5 for mRNA-1010. It’s for adults aged 50 and older.
Moderna proposed a regulatory pathway based on age, seeking full approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, along with a postmarketing requirement to conduct an additional study in older adults.
Moderna Analyst Sees Opportunity But Flags Some UncertaintiesWilliam Blair noted that the scope of Moderna's postmarketing commitments remains unclear. The company's willingness to fund potentially costly Phase IV studies are important given management's guidance to limit additional spending on its respiratory vaccine franchise.
Analyst Myles Minter said mFluSiva could become a meaningful driver of Moderna's revenue growth in 2027 if approved.
However, Minter maintained a Market Perform rating, citing the need for greater visibility into Phase 3 INTERPATH-001 data for intismeran in adjuvant melanoma, expected in 2026, which he views as a more significant long-term catalyst for the stock.
MRNA Stock Price Activity: Moderna shares rose 1.19% at $56.06 during premarket trading on Wednesday, according to Benzinga Pro data.
Photo: pcruciatti / Shutterstock
Market News and Data brought to you by Benzinga APIs
